Pliant Therapeutics Inc Total Liabilities
Pliant Therapeutics Inc total liabilities. Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has total liabilities worth $42.95 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Pliant Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pliant Therapeutics Inc (2017–2025)
Total liabilities of Pliant Therapeutics Inc from 2017 to 2025. This chart illustrates how Pliant Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Pliant Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Pliant Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Globaltec Formation Bhd
KLSE:5220
|
Malaysia | RM129.92 Million |
|
Seoul Auction Co. Ltd
KQ:063170
|
Korea | ₩118.07 Billion |
|
Yojee Ltd
AU:YOJ
|
Australia | AU$445.97K |
|
Fluoguide AS
ST:FLUO
|
Sweden | Skr31.70 Million |
|
Averbuch Formica Center Ltd
TA:AVER
|
Israel | ILA30.26 Million |
|
Santova Ltd
JSE:SNV
|
South Africa | ZAC1.05 Billion |
|
Accelerate Property Fund Ltd
JSE:APF
|
South Africa | ZAC4.13 Billion |
|
MGI Digital
PA:ALMDG
|
France | €38.03 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Pliant Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PLRX current and non-current assets.
Liquidity & Leverage Metrics
Pliant Therapeutics Inc Total Liabilities Ratios Explained
Pliant Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pliant Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pliant Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Pliant Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $44.02 Million | -52.60% |
| 2024-12-31 | $92.87 Million | +140.73% |
| 2023-12-31 | $38.58 Million | +3.51% |
| 2022-12-31 | $37.27 Million | +68.22% |
| 2021-12-31 | $22.16 Million | +77.75% |
| 2020-12-31 | $12.46 Million | -89.57% |
| 2019-12-31 | $119.50 Million | +77.27% |
| 2018-12-31 | $67.41 Million | +2014.52% |
| 2017-12-31 | $3.19 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more